Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study

CONCLUSIONS: An increasing proportion of patients received systemic treatment during the period 2010-18. However, less than 50% of patients in our study received systemic treatment. In accordance with updated guidelines, Docetaxel was introduced after 2015 with an increasing proportion of patients receiving systemic treatment as mHSPC. Further studies should address the disease course and treatment given to patients who do not receive systemic treatment.PMID:37725527 | DOI:10.1080/0284186X.2023.2257876

Source: Acta Oncologica - September 19, 2023 Category: Cancer & Oncology Authors: Anne Holck Stor ås Kaitlyn Tsuruda Sophie Dorothea Foss å Bettina Kulle Andreassen Source Type: research